Nidanilimab Biosimilar – Anti-IL1RAP mAb – Research Grade

Description of Nidanilimab Biosimilar - Anti-IL1RAP mAb - Research Grade

Introduction

Nidanilimab is a biosimilar antibody that targets the interleukin-1 receptor accessory protein (IL1RAP), a key molecule involved in the regulation of the immune system. This research grade antibody, also known as Anti-IL1RAP mAb, has shown promising results in preclinical studies and is now being evaluated for its potential therapeutic applications.

Structure of Nidanilimab

Nidanilimab is a monoclonal antibody (mAb) that is designed to mimic the structure and function of the endogenous human antibody against IL1RAP. It is a fully human IgG1 antibody, meaning it is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of about 20 days in human serum.

Activity of Nidanilimab

Nidanilimab acts by binding to IL1RAP, a protein that is expressed on the surface of various immune cells, including monocytes, macrophages, and dendritic cells. IL1RAP plays a crucial role in the activation of the immune system and is involved in the production of inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). These cytokines are known to contribute to the pathogenesis of various autoimmune and inflammatory diseases.

By binding to IL1RAP, Nidanilimab blocks the interaction between IL1RAP and its ligands, thereby inhibiting the downstream signaling pathways that lead to the production of pro-inflammatory cytokines. This mechanism of action makes Nidanilimab a potent immunosuppressive agent, with the potential to treat a wide range of inflammatory and autoimmune disorders.

Applications of Nidanilimab

Nidanilimab is currently being evaluated for its therapeutic potential in various diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In preclinical studies, Nidanilimab has shown promising results in reducing inflammation and improving disease symptoms in animal models of these diseases.

In addition, Nidanilimab has also been investigated in combination with other therapeutics, such as TNF-α inhibitors, with the aim of enhancing its efficacy and reducing the risk of developing drug resistance. This combination therapy has shown promising results in preclinical studies and is now being evaluated in clinical trials.

Research Grade Nidanilimab

The research grade version of Nidanilimab is primarily used for preclinical studies and research purposes. It is produced using state-of-the-art technology and undergoes rigorous quality control to ensure its purity, stability, and potency. This enables researchers to accurately evaluate the efficacy and safety of Nidanilimab in various disease models and to further understand its mechanism of action.

Conclusion

Nidanilimab, a biosimilar antibody targeting IL1RAP, has shown promising results in preclinical studies and is now being evaluated for its potential therapeutic applications in inflammatory and autoimmune diseases. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of these disorders. The research grade version of Nidanilimab provides a valuable tool for researchers to further explore its potential and contribute to the development of novel treatments for these diseases.